{
    "info": {
        "nct_id": "NCT04313504",
        "official_title": "An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients",
        "inclusion_criteria": "* Histologically, cytologically, or radiographically confirmed recurrent or metastatic non cutaneous HNSCC for which there are no surgical or radiation curative options.\n* ECOG performance status ≤2\n* Patients must be able to swallow pills\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Nasopharyngeal and salivary gland tumors\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy with the exception of alopecia\n* Prior exposure to both immunotherapy drugs (PD-1, PDL-1, CTLA-4 inhibitors) and PARP inhibitors. Single exposure to either immunotherapy or PARP inhibitors is allowable.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to niraparib or dostarlimab.\n* Patients with uncontrolled intercurrent illness.\n* Requirement of any use of steroids greater than the equivalent of 10mg prednisone daily is not allowed.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to swallow pills",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to swallow pills",
                    "criterion": "ability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically, cytologically, or radiographically confirmed recurrent or metastatic non cutaneous HNSCC for which there are no surgical or radiation curative options.",
            "criterions": [
                {
                    "exact_snippets": "Histologically, cytologically, or radiographically confirmed recurrent or metastatic non cutaneous HNSCC",
                    "criterion": "recurrent or metastatic non cutaneous HNSCC",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically",
                                "radiographically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which there are no surgical or radiation curative options",
                    "criterion": "curative options (surgical or radiation)",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Nasopharyngeal and salivary gland tumors",
            "criterions": [
                {
                    "exact_snippets": "Nasopharyngeal and salivary gland tumors",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "nasopharyngeal tumor",
                                "salivary gland tumor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have not recovered from adverse events due to prior anti-cancer therapy with the exception of alopecia",
            "criterions": [
                {
                    "exact_snippets": "Patients who have not recovered from adverse events due to prior anti-cancer therapy",
                    "criterion": "recovery from adverse events due to prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception_to_recovery_requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled intercurrent illness.",
            "criterions": [
                {
                    "exact_snippets": "Patients with uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to both immunotherapy drugs (PD-1, PDL-1, CTLA-4 inhibitors) and PARP inhibitors. Single exposure to either immunotherapy or PARP inhibitors is allowable.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to both immunotherapy drugs (PD-1, PDL-1, CTLA-4 inhibitors) and PARP inhibitors. Single exposure to either immunotherapy or PARP inhibitors is allowable.",
                    "criterion": "prior exposure to immunotherapy drugs and PARP inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "exposure history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to niraparib or dostarlimab.",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to niraparib or dostarlimab",
                    "criterion": "allergic reactions to compounds similar to niraparib or dostarlimab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requirement of any use of steroids greater than the equivalent of 10mg prednisone daily is not allowed.",
            "criterions": [
                {
                    "exact_snippets": "any use of steroids greater than the equivalent of 10mg prednisone daily is not allowed",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone daily"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}